Landmark UK Trial Shows Multi-Cancer Blood Test Reduces Stage IV Diagnoses Despite Missing Primary Endpoint

The largest randomized controlled trial of a multi-cancer early detection (MCED) blood test has released its highly anticipated results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The NHS-Galleri trial, involving over 142,000 asymptomatic adults in the United Kingdom, evaluated whether a single blood draw could reliably detect more than 50 types of cancer before symptoms appear. The findings present a complex landscape of evidence: while the test missed its primary statistical endpoint, it demonstrated a substantial ability to catch the most advanced and deadly cancers earlier than standard care.[1][2][3][4]

The Galleri test, developed by the biotechnology company GRAIL, operates on the frontier of liquid biopsy technology. It works by analyzing cell-free DNA (cfDNA)—microscopic fragments of genetic material that cells shed into the bloodstream as they die. Because cancer cells exhibit distinct epigenetic markers, specifically abnormal DNA methylation patterns, the test uses advanced sequencing and machine learning to identify these disease-specific signatures. If a cancer signal is detected, the algorithm also predicts the tissue of origin, guiding doctors on where to look next.[1][3][5]

Claim 1: The test reduces late-stage cancer diagnoses. The primary objective of the NHS-Galleri trial was to prove that annual screening could significantly reduce the combined number of Stage III and Stage IV diagnoses across 12 prespecified cancers. On this combined metric, the trial failed to meet its primary endpoint. The data showed no statistically significant reduction in aggregate Stage III and IV cancers between the group receiving the Galleri test and the control group receiving only standard care.[1][3][4][5]

However, a pre-planned secondary analysis of the data revealed strong evidence of tumor downstaging at the most critical threshold. When isolating Stage IV cancers—the most advanced and difficult to treat—the Galleri test achieved a 22% reduction in diagnoses during the second year of screening, and a 26% reduction in the third year. Oncologists note that this reduction is clinically meaningful, as the survival cliff between Stage III and Stage IV is severe; catching a tumor before it metastasizes widely often dictates whether treatment is curative or palliative.[1][4]

Claim 2: The test finds cancer before symptoms prompt emergency care. The evidence here is robust. The addition of the Galleri test to standard-of-care screenings resulted in a four-fold increase in the number of cancers detected through screening rather than clinical symptoms. Furthermore, the trial recorded a 25% decrease in cancers diagnosed after an emergency hospital presentation. Emergency diagnoses are historically associated with the poorest prognoses, making this reduction a major public health victory.[1][2][6]

Claim 3: The test is highly accurate and minimizes false alarms. The evidence for the test's accuracy is mixed, highlighting the inherent trade-offs in population-wide screening. On the positive side, the test demonstrated a remarkable specificity of 99.55%. This translates to a false positive rate of just 0.45%, meaning the vast majority of healthy individuals will not receive a terrifying false alarm.[1][2][6]

Despite this high specificity, the test's Positive Predictive Value (PPV) was 52.0%. Because cancer is relatively rare in the general asymptomatic population, a 0.45% false positive rate still generates a significant absolute number of incorrect signals. A 52% PPV means that for every 100 people who received a 'Cancer Signal Detected' result, only 52 were ultimately confirmed to have cancer after follow-up scans and biopsies. The remaining 48 underwent potentially stressful and expensive diagnostic workups for a cancer that was not present or could not be found.[1][3][5]

Claim 4: The test reliably detects all types of cancer. The evidence does not support this claim universally. The test's overall sensitivity—its ability to detect a cancer that is actually there—was 54.7% for the 12 prespecified deadliest cancers, but dropped to 30.7% across all cancer types. The technology is notably better at detecting later-stage, aggressive tumors that shed large amounts of DNA into the blood, while it frequently misses early-stage (Stage I and II) localized tumors.[1][2][5][6]

Where the test excelled was in its logistical utility once a signal was found. The 'Cancer Signal Origin' prediction was highly accurate, correctly identifying the primary site of the tumor in 92.5% of confirmed cases. This precision is crucial for healthcare systems, as it prevents patients from enduring a blind, full-body diagnostic hunt, directing them instead to the appropriate specialist—such as a pulmonologist or gynecologist—immediately.[1][2][6]

The interpretation of these mixed results has divided the medical community. Clinical optimists, including trial investigators and GRAIL executives, argue that the data represents a transformational shift. They emphasize that 70% of cancer deaths are caused by malignancies that currently have no routine screening, such as pancreatic, ovarian, and liver cancers. For these diseases, finding a tumor even a few months earlier via a blood test offers genuine hope where none previously existed.[1][2][3][4]

Conversely, evidence skeptics and independent researchers point to the missed primary endpoint as a sign that the technology is not yet ready for universal deployment. Critics argue that the 52% PPV and the low sensitivity for early-stage tumors mean the test could strain public health resources with unnecessary diagnostic scans while simultaneously giving false reassurance to those who receive a negative result but actually have an early-stage cancer.[3][5]

From a market perspective, the financial sector has responded favorably to the Stage IV reduction data. GRAIL recently reported strong fiscal performance, exceeding revenue expectations, and secured an additional $110 million in strategic equity financing. The company is also expanding its commercial footprint in the United States, partnering with health plans to offer the test to employer groups despite the lack of full FDA approval.[7]

The ultimate measure of the Galleri test's success remains an open question: does it save lives? While shifting diagnoses away from Stage IV is a strong surrogate marker for success, the NHS-Galleri trial does not yet have the long-term mortality data required to prove an overall survival benefit. It remains unknown whether all the cancers detected would have eventually become fatal, raising standard concerns about overdiagnosis.[2][4][6]

The path forward hinges on regulatory and public health reviews. The UK's National Health Service will spend the coming months analyzing the data to determine if the health economic benefits of avoiding late-stage treatments outweigh the costs of the test and the ensuing diagnostic workups. Meanwhile, the medical community eagerly awaits the results of the parallel US REACH trial, which will provide critical additional data to fully evaluate the population-level risks and rewards of multi-cancer early detection.[2][4][5][6]